Aleix Prat: Proud to be Co-author on Several Abstracts at ESMO Breast25
Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, posted on LinkedIn:
“Proud to be co-author on several abstracts at ESMO Breast25 next week in Munich — grateful to work with such talented colleagues advancing breast cancer research.
Two abstracts I’d like to highlight today:
1. A novel H and E-based classification of tertiary lymphoid structures (TLS) in breast cancer.
This study proposes a 5-tier histological TLS scoring system applied to nearly 1,000 tumors. TLS were enriched in HER2+ and TNBC subtypes and showed correlation with the HER2DX IGG signature — reinforcing its role as a prognostic and predictive immune biomarker. The IGG signature, also used in TNBCDX, was recently identified as a marker of long-term survival across subtypes, including HR+ (Angelats et al., ESMO Open 2025).
2. Central reassessment of HER2 status in HER2-positive tumors identified as ERBB2-low by HER2DX
This study reveals that most HER2+ tumors classified as ERBB2-low by HER2DX were reclassified as HER2-negative upon central pathology review. These findings support the ERBB2 score as a genomic tool to refine HER2 classification and guide potential retesting.
Congratulations to all presenting authors and teams involved!”
Read more posts featuring Aleix Prat.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023